Biotechgate, owned by Venture Valuation has partnered with Nasdaq GlobeNewswire to distribute Nasdaq’s GlobeNewswire press releases on Biotechgate and all its related country portals.
Through the collaboration, Biotechgate will provide Nasdaq GlobeNewswire with an additional worldwide and focused publication channel. Biotechgate will publish the Biotech and life science related news on its website www.biotechgate.com and make it available free of charge to all its users. In addition the GlobeNewswire press releases are made available step-by-step on the 30 country specific life sciences directories run by Biotechgate, such as the Swiss Life Sciences Database (www.swisslifesciences.com) or the UK Biotech Database (www.ukbiotech.com). Where possible, press releases are linked to the specific company profiles which are available in the global Biotechgate database.
Jost Renggli, COO of Venture Valuation / Biotechgate said: “This feed of news and press releases from GlobeNewswire adds great value to our global company directory. Users are able, not just to find new partners on our website, but also the latest news about the specific company.”
The Biotechgate Database is property of Venture Valuation AG, headquartered in Switzerland with offices in Singapore, UK, Ireland and the US. Biotechgate is a directory with more than 38,000 company profiles, pipeline products and management details. Life sciences executives around the globe use Biotechgate to identify new business partners or licensing opportunities. All data in the database is updated on an ongoing basis.
Zurich / Melbourne, November 2015: Venture Valuations Biotechgate and AusBiotech, the Australian Biotech Industry Association, have entered into an agreement to create a comprehensive directory of Australian biotechnology and life science companies and extend the network and reach of Biotechgate.
The Australian Life Sciences Directory will have a standalone web address and will also be a part of the larger Biotechgate global life science database (www.biotechgate.com), which includes more than 35,000 company profiles. Thanks to a comprehensive search form and automated alerts, it allows users to seek for specific companies filtering by sectors, indications, product phase and many other categories. Biotechgate produces directories for the largest life sciences clusters in the world, including BioCom in San Diego, Canada, France, Germany, Maryland, Sweden, Switzerland and UK.
Dr Anna Lavelle, CEO of Ausbiotech said: “We are pleased to be able to deliver this initiative in support of Australian biotech companies. Support tools like this new Australian directory help sector growth by enabling communication, linkages and access.”
Dr Patrik Frei, CEO of Venture Valuation said: “Increasing our Australian exposure has been important in the last 18 months and we are very happy to have one of the world’s most important biotech clusters as a partner. The database will help to provide foreign companies better access to innovative companies in Australia.”
The Biotechgate Database is the property of Venture Valuation AG, Switzerland. Biotechgate is a global life science database providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals and associated financial information on individual deals.
The Australian Life Sciences Directory will be initially set up with publicly available information via company websites and once launched and live, companies will be able to log in and update and tailor their details.
Patrik Frei, CEO Venture Valuation (on the left) is signing the contract with Glenn Cross, COO AusBiotech.
About us:
Biotechgate (www.biotechgate.com)
The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Science Database containing over 35,000 company profiles and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals and associated financial information on individual deals.
Venture Valuation AG (www.venturevaluation.com)
Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging life sciences companies (biotechnology, med-tech and pharma). Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland (Europe), Canada (North America) and Singapore (APAC), Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.
For further information, please contact: Patrik Frei, CEO Venture Valuation, contact@venturevaluation.com | +41 43 321 8660
Zurich / Singapore, November 2015 – Venture Valuation together with KPMG has released its 2015 Report on “Site Selection for Life Sciences companies in Europe”. The report looks across the European Life Sciences landscape, analysing and comparing 14 European countries. The report looks at the strength of Biotechnology, Medical Technology and Pharma.
This second edition report provides an in depth analysis of seven key life sciences clusters across Europe including Belgium, France, Germany, Ireland, Netherlands, Switzerland and the United Kingdom. These countries were chosen as they represent the main locations to attract direct foreign investment according to KPMG.
The data in the report is based on Venture Valuation’s global Biotechgate database with over 37,000 companies. In total 14 European countries including Austria, Denmark, Finland, Italy, Norway, Spain, Sweden (plus the 7 previously listed countries) are analysed along with Israel and the BayArea in the US. Venture Valuation analysed the number of Life Sciences companies in Biotechnology, Biotechnology – Therapeutics, Medical Technology and Pharma and reviewed their main activities with regards to R&D and manufacturing. A focus is also put on the numbers and activities of global and regional headquarters. The report provides information on the strength of the development pipeline, the therapeutic focus of each country and for each stage of development. Venture valuation also provides a detailed financial analysis on how much money has been raised by companies in the different countries, from the different sectors, looking at private and publicly listed companies.
Germany has the highest number of Biotechnology companies, however, the UK has the higher number of Biotechnology companies developing therapeutics, an indication for innovation. Regarding the pipeline, it is again the UK who leads, followed by Germany, France and Switzerland. In 2015 (Jan-Jul) UK and Swiss private companies raised around 75% of the total money raised by private European companies. Looking at public companies, Dutch and Irish companies raised the most alongside UK companies.
“This new report provides an excellent overview of the European Life Sciences Industry, especially focusing on private, unlisted companies. As this data is difficult to find, the small companies are often not included in such reports. With our unique global database, we can provide very detailed statistical information. Within Biotechgate, we have every single company / asset and financing round listed in our publicly available database, which provides transparency.” Dr. Patrik Frei, CEO of Venture Valuation / Biotechgate, Singapore/Switzerland
Biotechgate (www.biotechgate.com)
The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Science Database containing over 37,000 company profiles and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals and associated financial information on individual deals.
Venture Valuation AG (www.venturevaluation.com)
Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging life sciences companies (biotechnology, med-tech and pharma). Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland (Europe), Canada (North America) and Singapore (APAC), Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.
For further information, please contact: Patrik Frei, CEO Venture Valuation, Singapore contact@venturevaluation.com | +41 43 321 8660
Singapore / Taipei, June 2015 – Venture Valuation owned Biotechgate announces the partnership with Taiwan Bio Industry Organization to create a directory of Taiwanese Biotech companies. The database is the launch of a collaborative promotion of BIO Taiwan, one of the key Biotech and Life Sciences events in Asia.
The Taiwanese Biotech Directory (www.taiwanesebiotech.com and www.taiwaneselifesciences.com) are part of Biotechgate a global life science database, (www.biotechgate.com) which includes more than 35’000 company profiles. Thanks to a comprehensive search form and automated alerts, it allows users to seek for specific companies filtering by sectors, indications, product phase and many other categories. Taiwan Bio Industry Organization is the Biotech Organisation of Taiwan with over 400 members. Taiwan Bio is also the organizer of the yearly Bio Taiwan (July 22 to July 26, 2015 in Taipei). The database for Taiwan is launched to promote the companies of Taiwan, to provide them a window to the world and allow foreign companies to see the diversity in Taiwan Biotech Industry. Bio Taiwan is an ideal place for overseas companies to meet with innovative companies.
“Taiwan is a key cluster in Asia and we are happy to be part of the global Biotechgate database. Our BioTaiwan annual event is an important gathering of key opinion leaders, innovative companies in the region and had become popular also with overseas organisations.“ Dr. Johnsee Lee, Honorary Chairman of Taiwan BIO and the Chairman of BioTaiwan 2015 Organizing Committee.
“Increasing our Asian exposure has been key in the last 18 month and we are very happy to have one of the key Biotech clusters in the region as a partner. We are looking forward to participate in the BioTaiwan event this year in July. The database will help to provide foreign companies better access to innovation in Taiwan.” Dr. Patrik Frei, CEO of Venture Valuation / Biotechgate, Singapore/Switzerland
About us: Biotechgate (www.biotechgate.com) The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Science Database containing over 35’000 company profiles and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals and associated financial information on individual deals.
Venture Valuation AG (www.venturevaluation.com) Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging life sciences companies (biotechnology, med-tech and pharma). Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland (Europe), Canada (North America) and Singapore (APAC), Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.
Taiwan Bio Industry Organization (http://taiwanbio.org.tw/eng)
Taiwan Bio Industry Organization (TBIO) was established in 1989, is the largest and the most influential biotechnology organization in Taiwan. TBIO represents over 400 members ranging from private companies and academic institutes to government bodies involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology. Our mission is to provide advocacy, business development and communication service for our members. TBIO organize the annual BioTaiwan event, one of the largest gatherings of biotechnology industry in Asia. BioTaiwan 2015 will be held July 22-26 in Taipei (www.bio-taiwan.com) with series of BioBusiness Asia Conference, Conference on Greater China Opportunities, Company Presentation and One-on-one Partnering, seminars and workshops and exhibition with over 600 companies.
For further information, please contact: Patrik Frei, CEO Venture Valuation, Singapore+65 (31) 590 721, support@biotechgate.com
Switzerland / Finland, February 2015 – As a result of the partnership with Turku Science Park Ltd, Biotechgate gained its first partner in Finland. This partnership closes an important gap in the Nordic Life Science Database.
Turku Science Park (Finland) is now an official partner of Biotechgate and the Nordic Life Science Database. Thanks to this partnership, profiles of more than 200 life science companies from the region of Turku can be explored for free on www.nordic-lifesciences.com as well as on the website of Turku Science Park (www.turkusciencepark.com/fi/company-database). This directory is maintained and further completed on an ongoing basis.
The Finnish companies are also part of the global life science directory Biotechgate which contains profiles of more than 35,000 players from the Medtech, Biotech and Pharma field. Biotechgate also contains more detailed information on the Finnish company profiles, such as management contacts, financing rounds and product pipelines. Life Science executives use Biotechgate to identify emerging Biotech and Medtech companies, licensing opportunities, collaboration partners, etc. worldwide.Thanks to additional partners from Sweden, and Denmark, company profiles from these countries can be found and viewed for free on the Nordic Life Sciences Database. As a result of various search features the information is easily accessible.
“Joining Biotechgate was the result of a thorough analysis process to bring more business opportunities and visibility to Turku based life science companies and to BioTurku. We hope this will increase business and generate science co-operation between our region and companies globally.” Tero Karhi, Project Manager, Turku Science Park Oy Ltd
“Having Turku Science Park on board as a partner, means we can close an important gap in the Nordic Life Science Database and in Biotechgate. After our great experience with our existing partners in Norway, Sweden and Denmark, we are looking forward to seeing the Nordic region growing in our database. We are convinced this is a great contribution to life science executives inside and outside of Finland.” Jost Renggli, COO, Venture Valuation / Biotechgate
Switzerland /Norway, November 2014 – Biotechgate welcomes the three Norwegian partners Innovation Norway, Oslo Cancer Cluster and Nansen Neuroscience Network. This partnership further completes the Nordic Life Sciences Database which allows users to search for companies in the Biotech, Pharma and Medtech area.
More than 170 Norwegian companies can currently be found in the Nordic Life Sciences Database (www.nordic-lifesciences.com). All profiles are updated continuously and the database will be further completed with new profiles over the next months. Due to the partnerships with Innovation Norway, Oslo Cancer Cluster and Nansen Neuroscience Network, the database can be used free of charge. It is also possible for companies to publish their profile at no cost.
Thanks to additional partners from Sweden and Denmark, also Swedish and Danish profiles can be found and viewed for free on the Nordic Life Sciences Database. The portal is part of Biotechgate, a global life science directory which provides information such as product pipelines, management contact details, financing information and much more of more than 30,000 companies in the Biotech, Pharma and Medtech space. Thanks to various search features the information is easily accessible.
“Being the primary government agency for industry development, it is a priority for Innovation Norway to promote our prosperous life science community. Norway has close to 200 companies depending on biotechnology in their daily business and a total of more than 400 companies when looking at life sciences at large. We are very pleased to enter into this collaboration with Biotechgate together with our most prominent biomedical clusters in oncology and neuroscience, respectively.” Ole Jørgen Marvik, Sector Head, Health and Life Sciences, Innovation Norway
“Oslo Cancer Cluster is very pleased to have teamed up with Venture Valuation to profile our members through Biotechgate. We are reassured that this gives our SME-members a great exposure to the international VC and pharma milieu, which is important in our work to build a Norwegian Healthcare Industry.” Ketil Widerberg, General Manager, Oslo Cancer Cluster
“Our companies work to address important and complex challenges. Success will require collaborations and partnerships, and we believe that Biotechgate can be a powerful tool to help build those. We look forward to offering this to our members.” Leif Rune Skymoen, CEO of Nansen Neuroscience Network
“We are more than happy to close this gap in the Nordic Life Science Database. We are sure that having the Norwegian company profiles available on the database, will be a great contribution to all kind of actors active in the life sciences field – inside and outside of Norway and Scandinavia.” Jost Renggli, COO, Venture Valuation / Biotechgate
Switzerland /The Netherlands, Oct 2014 – Venture Valuation owned Biotechgate announces the partnership with HollandBIO to create a directory of Dutch Biotech, Pharma and Medtech companies. In addition the platform is supported by Medical Delta, the life sciences and medical technology cluster in the west of the Netherlands. The online directory makes it easier to find partners in the Netherlands and informs visitors about the Dutch life science industry.
The Dutch life science directory is part of Biotechgate a global life science database, (www.biotechgate.com) which includes more than 30’000 company profiles. Thanks to a comprehensive search form, it allows users to seek for specific companies filtering by sectors, indications, product phase and many other categories. The database is available at HollandBIO’s website, www.hollandbio.nl, as well as on the new version of the Dutch Life Science Database, www.dutchlifescience.com. In addition, a cluster specific directory can be found on Medical Delta’s website.
The user-friendly Dutch Life Science Database includes more than 1200 profiles of companies active in the Biotech, Pharma or Medtech sector. All profiles are updated continuously. The use of the database as well as being listed in the directory is free of charge. The Dutch platform is one of 30 country specific life science databases run and maintained by Venture Valuation.
“The Netherlands is home to a vibrant, dense biotechnology cluster. We are very pleased to provide more insights and foster the visibility of this cluster. The partnership with Biotechgate will allow visitors to easily access our broad network of Dutch Biotech, Pharma and Medtech companies, which makes the Dutch Life Science Database a perfect tool to promote the innovative Dutch life science sector.” Annemiek Verkamman, Director of HollandBIO
“We hope the new Dutch Life Science Database will contribute to the partnering activities in the Netherlands. We are delighted to welcome HollandBIO to our network of over 30 worldwide partners.” Jost Renggli, COO of Venture Valuation / Biotechgate
For further information, please contact:
Jost Renggli, COO Venture Valuation, Switzerland
+41 (43) 321 86 60 | support@biotechgate.com
Venture Valuation owned Biotechgate announces the launch of a new investor database. The goal of the new directory is to make the fundraising process for capital raising companies more effective and efficient.
An HTX led consortium, recently partnered with Biotechgate in launching a Canadian medtech sector specific database. Access to accurate data on the Canadian medtech sector along with other industry statistics is critical for aligning innovation and with key partners during various stages of product development and adoption. Over 20 medtech databases have been created in Canada over the last decade however, all suffer from single-organization mandates, limited data sets, and atrophy over time due to lack of regular maintenance and updates.
The HTX-led initiative, Medtech RISE, the Registry of Medtech Innovators, Suppliers and Exporters is a nationally focused initiative aimed at consolidating existing siloed databases and fostering local, national and international connectivity between researchers, customers, investors, collaborators, suppliers and world-class medtech companies. The culmination of data gathered through efforts of HTX, along with existing data on the Global Biotechgate database, has given rise to the only up-to-date and comprehensive Canadian medtech sector focused database of its kind. Data on Medtech RISE will be updated bi-annually to maintain relevancy and currency. Currently, Medtech RISE offers access to over 2700 Canadian medtech entities and is publicly accessible at www.htx.ca.
“Ontario is home to a vibrant medtech ecosystem, world-class medtech companies and expert R&D capacities. This partnership with Biotechgate will allow visitors to use our database to easily access a broad network of medtech focused organizations. Being a large geographic region, Canada has a number of regional medtech clusters with specific strengths that can now be easily mapped and accessed through the Canadian Medtech Asset Map. We are enthusiastic that this valuable tool will further collaborations and foster visibility of our medtech sector nationally and internationally.” Shahira Bhimani, Manager, Strategic Initiatives, HTX.
“We are very happy to welcome HTX and its collaborators to our global Biotechgate network of over 30 worldwide partners. We hope to further increase our reach in Canada and provide medtech stakeholders with another great tool while bringing more visibility, especially for smaller companies” Dr. Patrik Frei, CEO of Venture Valuation.
About us:
HTX, The Health Technology Exchange (www.htx.ca)
From Invention through Innovation to International Invoice, HTX provides non-dilutive project financing to emerging and established Ontario-based companies to develop, produce and commercialize innovative market-leading advanced health technologies. Through the Health Technology Commercialization Program (HTCP) and HTX’s MedTech ecosystem support activities, HTX is the leading resource and catalyst for accelerating the growth of Ontario’s MedTech industry, and enhancing Canada’s position as a global leader in commercializing innovative medical technologies. HTX manages a $21.4M fund on behalf of the Ontario Ministry of Research and Innovation and is a member of the Canadian Venture Capital Association. The HTCP program has levered over $70 M in total project funding from industry and strategic partners.
The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Sciences Database containing over 31’000 company profiles and providing the user with information on life science companies licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals and associated financial information on individual deals.
Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging high growth companies in industries such as biotechnology, med-tech and high-tech. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Germany, Canada and Asia, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.
Asian expansion – Venture Valuation is taking advantage of growth in Asia opening a new office in Singapore
ZURICH / SINGAPORE, December 2013 – Venture Valuation has recently opened its Asian office in Singapore to take advantage of the growing life sciences sector in Asia and to be even closer to its customers.
Having had clients from China, India, Japan, Korea and Singapore, Venture Valuation has opened up an office in one of the region’s most active life sciences centers – Singapore. Venture Valuation is offering company and product valuations to the growing number of investors in the Asia Pacific market. Especially family offices looking to invest in health care related businesses will benefit from the know-how and 14 years experience of Venture Valuation providing independent valuation services. Also Venture Capital and Corporate Investors as well as technology transfer offices have now the opportunity to work with Venture Valuation in the region. For emerging companies Venture Valuation will be able to provide valuation services for equity investments but also for M&A activities. For any in- or out-licensing, Venture Valuation offers its tailored product valuations.
Beside the valuation services, Venture Valuation offers its global Life Sciences database, Biotechgate with over 30’000 company profiles, licensing opportunities, financing rounds, management details and pipeline products. Asian companies looking for in-licensing of North American or European products will find opportunities not available in any other database or directory. Biotechgate focuses on the smaller, private companies and thus has a unique offering of dataset.
Venture Valuation can now provide the perfect bridge between Asia, Europe and North America, having offices on all three continents. As biotech, life sciences and health care are international industries, Venture Valuation can offer a truly global coverage and experience.
For further information: Dr. Patrik Frei, CEO, p.frei (at) venturevaluation.com
Venture Valuation VV Asia Pte. Ltd.
165 Bukit Merah Central, #05-3679
Singapore 150165
Phone: +65 (94) 570 580
About us:
Venture Valuation (www.venturevaluation.com)
Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging high growth companies in industries such as biotechnology, med-tech and high-tech. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries. Furthermore, Venture Valuation has initiated, maintains and provides the Biotech and Life Sciences Database Biotechgate (www.biotechgate.com), along with many country databases including in Canada (www.canadianlifesciences.com), France (www.frenchbiotech.com), Germany (www.germanbiotech.com), Scandinavia (www.scandinavianlifesciences.com), Switzerland (www.swisslifesciences.com), UK (www.ukbiotech.com) and the US (www.usalifesciences.com).
